<DOC>
	<DOCNO>NCT02235662</DOCNO>
	<brief_summary>The purpose study evaluate safety TFV/LNG intravaginal ring ( IVR ) , TFV-only IVR , placebo IVR , evaluate pharmacokinetics ( PK ) TFV LNG , evaluate pharmacodynamic ( PD ) surrogates contraceptive efficacy LNG , evaluate acceptability IVRs .</brief_summary>
	<brief_title>Phase I One-month Safety , PK , PD , Acceptability Study IVR Releasing TFV LNG TFV Alone</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 1845 year , inclusive General good health ( volunteer history per investigator discretion ) without clinically significant systemic disease ( include , limited significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , diabetes ) Currently regular menstrual cycle 2635 day participant report History Pap smear followup consistent standard medical practice outline study manual willing undergo Pap smear Protected pregnancy one following : 1 ) Sterilization either partner . Note : Women protect pregnancy sterilization either partner must abstain vaginal intercourse 48 hour prior Visit 3 sixth day last study visit ; 2 ) Willing abstain vaginal intercourse Visit 1 sixth day last study visit . Willing abstain vaginal activity use vaginal product study product include tampon , spermicide , lubricant , douche start 48 hour Visit 3 sixth day last study visit Vaginal cervical anatomy , opinion investigator , lend easy colposcopy genital tract sample collection Negative urine pregnancy test P4 ≥3 ng/ml Willing give voluntary consent , sign inform consent form comply study procedure require protocol History hysterectomy Currently pregnant within two calendar month last pregnancy outcome . Note : If recently pregnant must least two spontaneous menses since pregnancy outcome . Use hormonal contraceptive method last 3 month ( oral , transdermal , transvaginal , implant , hormonal intrauterine contraceptive device ) Injection DepoProvera last 10 month Use copper intrauterine device ( IUD ) Visit 1 Currently breastfeed breastfed infant last two month , plan breastfeed course study History sensitivity/allergy component : TFV 1 % gel , topical anesthetic , allergy silver nitrate Monsel 's solution . Contraindication LNG In last six month , diagnose treat sexually transmit infection ( STI ) pelvic inflammatory disease . Note : Women history genital herpes condylomata asymptomatic least six month may consider eligibility . Nugent score great equal 7 symptomatic bacterial vaginosis ( BV ) define Amsel 's criterion Positive test Trichomonas vaginalis , Neisseria gonorrhea ( GC ) , Chlamydia trachomatis ( CT ) , HIV , Hepatitis B surface antigen ( HBsAg ) Known bleed disorder could lead prolonged continuous bleed biopsy Chronic acute vulvar vaginal symptom ( pain , irritation , spot , etc . ) Known current drug alcohol abuse could impact study compliance Grade 2 high laboratory abnormality , per August 2009 update Division AIDS , National Institute Allergy Infectious Disease ( DAIDS ) Table Grading Severity Adverse Events , clinically significant laboratory abnormality determine clinician Systemic use last two week anticipate use study follow : corticosteroid , antibiotic , anticoagulant drug know prolong bleed and/or clotting , antifungal , antiviral ( e.g. , acyclovir valacyclovir ) antiretrovirals ( e.g. , Viread , Atripla® , Emtriva® , Complera® ) . Note : Participants avoid nonsteroidal antiinflammatory drug ( NSAIDs ) except treatment dysmenorrhea menses . Participants may use Tylenol® asneeded daily basis study Participation investigational trial ( device , drug , vaginal trial ) within last 30 day plan participation investigational trial study History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix within last 14 day Abnormal find laboratory physical examination social medical condition , opinion investigator , would make participation study unsafe would complicate interpretation data</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>LNG</keyword>
	<keyword>IVR</keyword>
	<keyword>Contraception</keyword>
	<keyword>Prevention</keyword>
</DOC>